Tag: Blood Disorders
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups
Oral Switch Noninferior for Low-Risk S. Aureus Bloodstream Infection
Early oral antimicrobial therapy noninferior to intravenous standard therapy for low-risk bloodstream infection
FDA Approves Casgevy to Treat Beta-Thalassemia
Casgevy is the first CRISPR-based medicine to be approved for use in the United States
Imetelstat Leads to Durable Red Blood Cell Transfusion Independence
Findings seen in heavily transfused patients with lower-risk myelodysplastic syndromes
American Society of Hematology, Dec. 9 to 12
Hematocrit Within Normal Range With Testosterone Gender-Affirming Therapy
Mean hematocrit ranged from 41.84 to 45.68 percent for those receiving testosterone as gender-affirming hormone therapy
FDA Approves First Treatment for Congenital Thrombotic Thrombocytopenic Purpura
The genetically engineered protein product is safe, effective for the rare inherited blood clotting disorder
Tolerable Treatments Lacking for Higher-Risk Myelodysplastic Syndromes
61 percent of 200 patients with higher-risk MDS were subsequently hospitalized within six months of diagnosis
Efgartigimod Efficacious, Safe for Primary Immune Thrombocytopenia
More patients receiving efgartigimod reached primary end point of sustained platelet count response
Risk for Intracerebral Hemorrhage May Be Transmissible Via Blood Transfusion
Risk was increased for those receiving transfusion from donors who later developed multiple spontaneous intracerebral hemorrhages
